The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Asunercept (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- Sponsors CANbridge Life Sciences
- 21 Sep 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
- 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
- 18 May 2017 New trial record